Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status
Helicobacter pylori infection shows a worldwide prevalence of around 50%. However, only a minority of infected individuals develop clinical symptoms or diseases. The presence of H. pylori virulence factors, such as CagA and VacA, has been associated with disease development, but assessment of virule...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2017/8394593 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545814669426688 |
|---|---|
| author | Luca Formichella Laura Romberg Hannelore Meyer Christian Bolz Michael Vieth Michael Geppert Gereon Göttner Christina Nölting Wolfgang Schepp Arne Schneider Kurt Ulm Petra Wolf Ingrid Lisanne Holster Ernst J. Kuipers Bernd Birkner Erwin Soutschek Markus Gerhard |
| author_facet | Luca Formichella Laura Romberg Hannelore Meyer Christian Bolz Michael Vieth Michael Geppert Gereon Göttner Christina Nölting Wolfgang Schepp Arne Schneider Kurt Ulm Petra Wolf Ingrid Lisanne Holster Ernst J. Kuipers Bernd Birkner Erwin Soutschek Markus Gerhard |
| author_sort | Luca Formichella |
| collection | DOAJ |
| description | Helicobacter pylori infection shows a worldwide prevalence of around 50%. However, only a minority of infected individuals develop clinical symptoms or diseases. The presence of H. pylori virulence factors, such as CagA and VacA, has been associated with disease development, but assessment of virulence factor presence requires gastric biopsies. Here, we evaluate the H. pylori recomLine test for risk stratification of infected patients by comparing the test score and immune recognition of type I or type II strains defined by the virulence factors CagA, VacA, GroEL, UreA, HcpC, and gGT with patient’s disease status according to histology. Moreover, the immune responses of eradicated individuals from two different populations were analysed. Their immune response frequencies and intensities against all antigens except CagA declined below the detection limit. CagA was particularly long lasting in both independent populations. An isolated CagA band often represents past eradication with a likelihood of 88.7%. In addition, a high recomLine score was significantly associated with high-grade gastritis, atrophy, intestinal metaplasia, and gastric cancer. Thus, the recomLine is a sensitive and specific noninvasive test for detecting serum responses against H. pylori in actively infected and eradicated individuals. Moreover, it allows stratifying patients according to their disease state. |
| format | Article |
| id | doaj-art-cc04bfb5142748dba8cdecdb11ca8b45 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-cc04bfb5142748dba8cdecdb11ca8b452025-02-03T07:24:48ZengWileyJournal of Immunology Research2314-88612314-71562017-01-01201710.1155/2017/83945938394593Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication StatusLuca Formichella0Laura Romberg1Hannelore Meyer2Christian Bolz3Michael Vieth4Michael Geppert5Gereon Göttner6Christina Nölting7Wolfgang Schepp8Arne Schneider9Kurt Ulm10Petra Wolf11Ingrid Lisanne Holster12Ernst J. Kuipers13Bernd Birkner14Erwin Soutschek15Markus Gerhard16Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, GermanyInstitute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, GermanyInstitute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, GermanyInstitute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, GermanyDepartment of Pathology, Klinikum Bayreuth, Bayreuth, GermanyPrivate Practice for Gastroenterology, Alexanderstr. 2, 95444 Bayreuth, GermanyMikrogen GmbH, Neuried, GermanyMikrogen GmbH, Neuried, GermanyDepartment of Gastroenterology, Hepatology and Gastrointestinal Oncology, Bogenhausen Academic Teaching Hospital, Munich, GermanyDepartment of Gastroenterology, Hepatology and Gastrointestinal Oncology, Bogenhausen Academic Teaching Hospital, Munich, GermanyInstitute for Medical Statistics and Epidemiology, Technische Universität München, Munich, GermanyInstitute for Medical Statistics and Epidemiology, Technische Universität München, Munich, GermanyErasmus MC University Medical Center, Gastroenterology and Hepatology Rotterdam, Rotterdam, NetherlandsErasmus MC University Medical Center, Gastroenterology and Hepatology Rotterdam, Rotterdam, NetherlandsPrivate Practice for Gastroenterology, Einsteinstraße 1, 81675 Munich, GermanyMikrogen GmbH, Neuried, GermanyInstitute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, GermanyHelicobacter pylori infection shows a worldwide prevalence of around 50%. However, only a minority of infected individuals develop clinical symptoms or diseases. The presence of H. pylori virulence factors, such as CagA and VacA, has been associated with disease development, but assessment of virulence factor presence requires gastric biopsies. Here, we evaluate the H. pylori recomLine test for risk stratification of infected patients by comparing the test score and immune recognition of type I or type II strains defined by the virulence factors CagA, VacA, GroEL, UreA, HcpC, and gGT with patient’s disease status according to histology. Moreover, the immune responses of eradicated individuals from two different populations were analysed. Their immune response frequencies and intensities against all antigens except CagA declined below the detection limit. CagA was particularly long lasting in both independent populations. An isolated CagA band often represents past eradication with a likelihood of 88.7%. In addition, a high recomLine score was significantly associated with high-grade gastritis, atrophy, intestinal metaplasia, and gastric cancer. Thus, the recomLine is a sensitive and specific noninvasive test for detecting serum responses against H. pylori in actively infected and eradicated individuals. Moreover, it allows stratifying patients according to their disease state.http://dx.doi.org/10.1155/2017/8394593 |
| spellingShingle | Luca Formichella Laura Romberg Hannelore Meyer Christian Bolz Michael Vieth Michael Geppert Gereon Göttner Christina Nölting Wolfgang Schepp Arne Schneider Kurt Ulm Petra Wolf Ingrid Lisanne Holster Ernst J. Kuipers Bernd Birkner Erwin Soutschek Markus Gerhard Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status Journal of Immunology Research |
| title | Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status |
| title_full | Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status |
| title_fullStr | Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status |
| title_full_unstemmed | Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status |
| title_short | Validation of a Novel Immunoline Assay for Patient Stratification according to Virulence of the Infecting Helicobacter pylori Strain and Eradication Status |
| title_sort | validation of a novel immunoline assay for patient stratification according to virulence of the infecting helicobacter pylori strain and eradication status |
| url | http://dx.doi.org/10.1155/2017/8394593 |
| work_keys_str_mv | AT lucaformichella validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT lauraromberg validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT hanneloremeyer validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT christianbolz validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT michaelvieth validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT michaelgeppert validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT gereongottner validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT christinanolting validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT wolfgangschepp validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT arneschneider validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT kurtulm validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT petrawolf validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT ingridlisanneholster validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT ernstjkuipers validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT berndbirkner validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT erwinsoutschek validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus AT markusgerhard validationofanovelimmunolineassayforpatientstratificationaccordingtovirulenceoftheinfectinghelicobacterpyloristrainanderadicationstatus |